Emerald Advisers Inc. PA Has $34.75 Million Holdings in Sarepta Therapeutics Inc (SRPT)

Emerald Advisers Inc. PA lowered its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 28.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,148 shares of the biotechnology company’s stock after selling 84,196 shares during the period. Sarepta Therapeutics makes up approximately 1.3% of Emerald Advisers Inc. PA’s holdings, making the stock its 17th biggest position. Emerald Advisers Inc. PA owned about 0.32% of Sarepta Therapeutics worth $34,749,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. FMR LLC lifted its position in shares of Sarepta Therapeutics by 0.9% in the second quarter. FMR LLC now owns 9,749,879 shares of the biotechnology company’s stock worth $1,288,739,000 after buying an additional 82,453 shares during the last quarter. RTW Investments LP lifted its position in shares of Sarepta Therapeutics by 42.2% in the second quarter. RTW Investments LP now owns 978,551 shares of the biotechnology company’s stock worth $129,345,000 after buying an additional 290,280 shares during the last quarter. Millennium Management LLC lifted its position in shares of Sarepta Therapeutics by 242.2% in the second quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock worth $113,464,000 after buying an additional 607,588 shares during the last quarter. Waddell & Reed Financial Inc. acquired a new stake in shares of Sarepta Therapeutics in the second quarter worth about $103,682,000. Finally, Renaissance Technologies LLC lifted its position in shares of Sarepta Therapeutics by 93.7% in the second quarter. Renaissance Technologies LLC now owns 495,478 shares of the biotechnology company’s stock worth $65,492,000 after buying an additional 239,700 shares during the last quarter. 89.57% of the stock is owned by institutional investors.

Sarepta Therapeutics stock opened at $124.43 on Wednesday. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $8.13 billion, a price-to-earnings ratio of -75.87 and a beta of 1.16. Sarepta Therapeutics Inc has a 12 month low of $47.25 and a 12 month high of $176.50.



Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.29). The firm had revenue of $78.49 million during the quarter, compared to analyst estimates of $78.84 million. Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 22.76%. As a group, analysts expect that Sarepta Therapeutics Inc will post -3.99 earnings per share for the current fiscal year.

A number of analysts have weighed in on SRPT shares. Morgan Stanley raised Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and set a $163.00 price target for the company in a research report on Wednesday, August 1st. Cantor Fitzgerald started coverage on Sarepta Therapeutics in a research report on Monday, October 1st. They issued an “overweight” rating and a $217.00 price target for the company. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 9th. Credit Suisse Group assumed coverage on Sarepta Therapeutics in a research report on Thursday, September 6th. They set an “outperform” rating and a $178.00 price objective for the company. Finally, Bank of America assumed coverage on Sarepta Therapeutics in a research report on Friday, September 14th. They set a “buy” rating and a $199.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twenty-five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $168.37.

In other news, CEO Douglas S. Ingram purchased 16,695 shares of the business’s stock in a transaction on Tuesday, October 30th. The stock was purchased at an average price of $120.39 per share, with a total value of $2,009,911.05. Following the acquisition, the chief executive officer now directly owns 412,811 shares in the company, valued at approximately $49,698,316.29. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Douglas S. Ingram purchased 16,000 shares of the business’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average cost of $125.26 per share, with a total value of $2,004,160.00. Following the acquisition, the chief executive officer now owns 399,250 shares in the company, valued at $50,010,055. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: Inflation

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply